

## SARS CoV-2 Spike Glycoprotein South Africa variant Positive Control for STJ506303 peptide (South Africa variant) (STJ506307)

STJ506307

### GENERAL INFORMATION

<b>Product Type</b>	Biomolecules
<b>Short Description</b>	SARS CoV-2 Spike Glycoprotein South Africa variant Positive Control for STJ506303 is synthetically produced from the 400-450 sequence about the South Africa variant and is suitable for use in western blot applications.
<b>Applications</b>	WB
<b>Host/Source</b>	
<b>Reactivity</b>	

### PRODUCT PROPERTIES

<b>Clonality</b>	
<b>Clone ID</b>	
<b>Concentration</b>	
<b>Conjugation</b>	
<b>Purification</b>	
<b>Dilution</b>	
<b>Range</b>	
<b>Formulation</b>	Provided as 100 uL ready-to-use, in SDS-PAGE sample buffer (Laemelli's buffer) containing Tris, pH 6.8, 1 % SDS, Glycerol and Bromophenolblue blue as tracking dye. The sample is reduced by adding 2% beta mercaptoethanol. The protein concentration is
<b>Isotype</b>	
<b>Storage</b>	Store at -20°C for long term storage. Avoid freeze-thaw cycles.
<b>Instruction</b>	

### TARGET INFORMATION

<b>Gene ID</b>	
<b>Gene Symbol</b>	
<b>Uniprot ID</b>	
<b>Immunogen</b>	400-450
<b>Immunogen</b>	400-450
<b>Region</b>	
<b>Specificity</b>	This is positive control is recommended for use in combination with SARS CoV-2 Spike Glycoprotein South Africa variant antibody STJ506303.
<b>Immunogen</b>	
<b>Sequence</b>	